Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding supports organizations providing independent healthcare professional education to strengthen knowledge and skills and better meet patient and community needs.
Funder: Johnson & Johnson (Janssen)
Due Dates: Approximately November 1, 2026 (anticipated portal availability, not a deadline) | 2027 requests accepted only after ITCI portal availability
Funding Amounts: No ITCI-specific award amount or funding range published
Summary: Supports organizations providing independent healthcare professional education to strengthen knowledge and skills and better meet patient and community needs.
Key Information: Email submissions must include accreditation status and a valid accreditation certificate showing its expiration date.
Description
Intra-Cellular Therapies, Inc. (ITCI) Corporate Funding is part of Johnson & Johnson Innovative Medicine’s educational-grant program. The program supports organizations delivering independent training and continuing medical education for healthcare professionals, including physicians, nurses, residents, and pharmacists. Its goal is to strengthen professional knowledge and skills so healthcare professionals can better meet patient and community needs.
The broader educational-grant program’s interests include neuroscience, oncology, and immunology, alongside initiatives supporting communities facing barriers to equitable healthcare access and representation. These are shared program interests, not a separate ITCI-only therapeutic scope.
